Targets › HRH2
3 programs from 3 companies in 3 trials: 2 Phase 4, 1 Phase 3; Gastroenterology, Other, Immunology; next expected readout Dec 2027.
G protein-coupled receptor for histamine, primarily mediating gastric acid secretion. Predominantly expressed in the gastric mucosa, couples to G(s) G alpha proteins upon histamine binding, leading to activation of adenylate cyclase and increased intracellular cyclic AMP (cAMP) levels. (UniProt, P25021)
Open in Phaseline: the race on HRH2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stony Brook University | Famotidine Histamine H2 receptor antagonist | HRH2 | Phase 4 | Dyspepsia | Dec 2027 |
| University of Washington | Cimetidine Histamine H2 receptor antagonist | HRH2 | Phase 4 | Postpartum | Sep 2028 |
| The University of Texas Medical Branch, Galveston | Famotidine Histamine H2 receptor antagonist | HRH2 | Phase 3 | Burn Scar | Dec 2027 |
Dyspepsia (1) Postpartum (1) Burn Scar (1)
small molecule (3)
Stony Brook University (1) University of Washington (1) The University of Texas Medical Branch, Galveston (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.